REVENUE (Tables)

3 Months Ended

Jan. 31, 2022

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Three Months Ended January 31
	2022								2021
	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total		Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Revenue by Region
Americas	$	317	$	132	$	188	$	637	$	279	$	124	$	152	$	555
Europe	252		98		101		451		245		92		100		437
Asia Pacific	407		129		50		586		399		115		42		556
Total	$	976	$	359	$	339	$	1,674	$	923	$	331	$	294	$	1,548

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


	Three Months Ended
	January 31
	2022		2021
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical	$	602	$	521
Chemical and Energy	373		328
Diagnostics and Clinical	243		216
Food	158		162
Academia and Government	141		142
Environmental and Forensics	157		179
Total	$	1,674	$	1,548

Revenue by Type
Instrumentation	$	691	$	681
Non-instrumentation and other	983		867
Total	$	1,674	$	1,548

Contract Liabilities and Changes in Balances

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2022:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2021	$	519
Net revenue deferred in the period	220
Revenue recognized that was included in the contract liability balance at the beginning of the period	(191)
Change in deferrals from customer cash advances, net of revenue recognized	34

Currency translation and other adjustments	(6)
Ending balance as of January 31, 2022	$	576